Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
IBSA Institut Biochimique SA is a privately owned, pharmaceutical company founded in 1945 by a group of Swiss biologists. Based in Lugano, Switzerland, IBSA started its activities at a national level but rapidly became a well consolidated company worldwide. IBSA markets its products in 4 continents which means more than 70 countries, including the US. IBSA’s history can be divided into 2 main periods from its beginning 1945 to 1985 when the current management took over and completely re-defined the company strategy leading to the first international development and to its present global reputation.
As a result of this massive commercial revolution, IBSA currently has a head count of about 1800 employees and its products cover 7 main therapeutic areas in 4 continents and more than 70 countries. Each year the company manufactures about 12 millions vials of hormones, more than 200 millions soft gel capsules and about 60 millions packages of finished products. These are the numbers of a well-deserved success.
The company’s first foreign subsidiary was founded in 1995 in Budapest, Hungary. The subsidiary has 21 years of unbroken success, with a dedicated and hardworking staff whose efforts truly demonstrate the impeccable quality and competitive prices that the IBSA brand embodies.
Contact
1124 Budapest, Fodor u. 54 / B
Tel: (1) 225-7775
Fax: (1) 201-7772
Email: ibsa@ibsa.hu
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
To effectively reform old habits requires diligence, consistency and, above all, patience. As an introduction for our readers, could you describe the initial objectives that you set for yourself…
The pharmaceutical industry is one of the pillars of the Hungarian economy and has been identified as a key growth driver for the future by the government of Prime Minister…
Dr. Zsuzsanna Fürst, President of the Ethics Committee for Clinical Pharmacology, elaborates on the role and activities of the ethics committee, shares her insights on structural framework of the application…
Dr Beata Sperlagh, Deputy Director of the Institute of Experimental Medicine (IEM), shares her insights on the institute’s involvement in research and with the private sector, the key strengths of…
Irisz Lippai-Nagy, CEO of AmCham Hungary, shares insights on the drivers contributing to economic growth in Hungary, recent policies and reforms, the role of the association, and policy recommendations to…
Oliver Strommer, newly appointed executive director of the British Chamber of Commerce in Hungary (BCCH), introduces the Chamber and its refocused aim of becoming a more dynamic player in business…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
Hungary’s Minister of Finance Mihály Varga has repeatedly underlined the importance of the pharmaceutical industry to the country’s economy in recent weeks. With this strong governmental backing, pharma stands to…
Hungary has long been one of the leading countries in Central and Eastern Europe for clinical trials. However, a downward trend in the number of research projects being conducted in…
Cancer is on the rise in Hungary and survival rates are considerably lower than the European average. The country’s innovative pharma association has taken the initiative to suggest measures that…
See our Cookie Privacy Policy Here
